Autoimmune Liver Disease
7
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
A Study of SIPLIZUMAB in AILD and LT Patients
TruGraf Liver Gene Expression Serial Test
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G
Patterns and Outcome of Autoimmune Related Liver Disease
Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease